Regeneron

YTD

ALL

Trade Regeneron 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.

CEO

Leonard S. Schleifer

CEOLeonard S. Schleifer

Employees

15,106

Employees15,106

Headquarters

Tarrytown, New York

HeadquartersTarrytown, New York

Founded

1988

Founded1988

Employees

15,106

Employees15,106

REGN Key Statistics

Market cap

61.26B

Market cap61.26B

Price-Earnings ratio

14.69

Price-Earnings ratio14.69

Dividend yield

0.16%

Dividend yield0.16%

Average volume

1.23M

Average volume1.23M

High today

$563.91

High today$563.91

Low today

$545.00

Low today$545.00

Open price

$548.07

Open price$548.07

Volume

827.65K

Volume827.65K

52 Week high

$1,211.20

52 Week high$1,211.20

52 Week low

$525.99

52 Week low$525.99

REGN News

TipRanks 19h

Regeneron, Sanofi announce FDA approval of Dupixent for CSU

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the U.S. Food and Drug Administration has approved Dupixent for the treatment of adults and ado...

Benzinga 2d

FDA Sets The Countdown: Regeneron's Eylea HD Could Be Headed For Major Expansion

The U.S. Food and Drug Administration has accepted for Priority Review Regeneron Pharmaceuticals, Inc.’s REGN supplemental Biologics License Application (sBLA)...

TipRanks 2d

Regeneron Downgraded to Sell Amid Eylea Sales Decline and Market Pressures

Bank of America Securities analyst Tim Anderson reiterated a Sell rating on Regeneron (REGN – Research Report) today and set a price target of $547.00. Tim And...

Analyst ratings

67%

of 27 ratings

Buy

66.7%

Hold

29.6%

Sell

3.7%

More REGN News

TipRanks 3d

Regeneron’s odronextamab granted FDA orphan designation

Regeneron’s (REGN) odronextamab was granted FDA orphan designation as a treatment of splenic marginal zone lymphoma, according to a post to the agency’s website...

TipRanks 4d

Resilient Outlook: Regeneron’s Strong Financial Projections Amid Foundation Closure Challenges

Leerink Partners analyst David Risinger has maintained their bullish stance on REGN stock, giving a Buy rating on April 11. David Risinger has given his Buy ra...